Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22069562 | 0.91 | PDE7A (0.74) | PDE7AMEN1KMT2AGAAPKM | |
| SCHEMBL10962798 | 0.86 | PDE7A (0.63) | PDE7AMEN1KMT2AGAAPKM | |
| Nitrofen SCHEMBL29364713 | 0.84 | PDE7A (0.68) | PDE7AMEN1KMT2AGAAPKM | |
| SCHEMBL11160178 | 0.84 | HSPB1 (0.55) | PDE7AMEN1KMT2AGAAPKM | |
| Nitrofen SCHEMBL38981 | 0.84 | PDE7A (0.68) | PDE7AMEN1KMT2AGAAPKM | |
| Nitrofen SCHEMBL1702412 | 0.84 | PDE7A (0.68) | PDE7AMEN1KMT2AGAAPKM | |
| Nitrofen SCHEMBL28057303 | 0.83 | PDE7A (0.67) | PDE7AMEN1KMT2AGAAPKM | |
| SCHEMBL10858973 | 0.82 | TDP1 (0.51) | PDE7AMEN1KMT2AGAAPKM | |
| SCHEMBL10564929 | 0.82 | HSPB1 (0.73) | PDE7AMEN1KMT2AHSPB1ALDH1A1 | |
| SCHEMBL31287820 | 0.82 | HSPB1 (0.73) | PDE7AMEN1KMT2AHSPB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656963-B2 | Dihydropyrazole GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2925726-B1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160280659-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-09-29 | — | — | US | disclosed |
| EP-2925726-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014078608-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-22 | — | — | WO | disclosed |
| EP-0848703-A1 | DERIVATIVES OF BENZOSULPHONAMIDES AS INHIBITORS OF THE ENZYME CYCLO-OXYGENASE II | Nycomed Austria GmbH (AT) | 1998-06-24 | — | — | EP | disclosed |
| WO-1997003953-A1 | DERIVATIVES OF BENZOSULPHONAMIDES AS INHIBITORS OF THE ENZYME CYCLO-OXYGENASE II | NYCOMED AUSTRIA GMBH (AT) | 1997-02-06 | — | — | WO | disclosed |
| US-5276037-A | Antiinflammatory agents, antiallergens | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-04 | — | — | US | disclosed |
| US-5272173-A | 5-lipoxygenase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-21 | — | — | US | disclosed |
| US-5225438-A | Lipoxygenase inhibitors for antiinflammatory agents or antiallergens | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-07-06 | — | — | US | disclosed |
| EP-0488602-A1 | Aryl derivatives | ZENECA LIMITED (GB) | 1992-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280659-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | GPR55, GPR35, GPR65 | PDE7A 618/4885MEN1 3897/4885KMT2A 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.